Anthracycline doxorubicin-resistant carbonyl reductase-1 knock out mice

C04211: Anthracycline doxorubicin-resistant carbonyl reductase-1 knock out mice
Technical Details:
The cancer treatment drug doxorubicin (brand name adriamycin) is very effective against tumors, but causes a serious side effect of heart damage. This toxicity occurs in part because the enzyme carbonyl reductase metabolizes the drug into a cardiotoxic form. We created mice with one non-functional copy of the carbonyl reductase 1 gene. These mice are substantially protected against the heart damage that occurs in normal mice treated with doxorubicin.
Looking for Partners:
This trangenic mouse line can serve as a reference for drug screening of compounds that protect against the cardiotoxicity of adriamycin by inhibiting carbonyl reductase.

Category(s):